Experience in clinical using normobact l sinbiotic in combination therapy of acute intestinal infections of virus etiology in children
https://doi.org/10.21518/2079-701X-2018-11-154-157
Abstract
The article presents the results of using Normobact L Synbiotic for the treatment of acute intestinal infections (AII) in children. The study included 60 children aged between 6 months and 6 years with a clinical diagnosis of AII, acute gastroenteritis of viral etiology. The average age of patients enrolled was 2.6 years, with 46.7% (28/60) girls. The treatment of AII was carried out in accordance with the clinical guidelines for the management of acute intestinal infections and included pathogenetic and symptomatic therapy. In addition, the study groupa recieved the biologically active additive (BAA) Normobact L (manufacturer Akrikhin, Russia) containing a probiotic strain Lactodacillus rhamnosus GG. According to the ESPGHAN guidelines, this strain has the largest evidence base of efficacy in the treatment of AII [8]. Synbiotic Normobact L was used at a dose of 1 sachet once daily for 7 days. In the comparison group, the patients received Bifidumbacterin in the amount 15 doses divided into 3 daily intakes for 7 days in addition to pathogenetic and symptomatic therapy. The obtained data analysis showed that diarrheal syndrome ceased earlier in the group of children who received Normobact L. The stool became normal 1.19 days sooner than in the group of children receiving Bifidumbacterin. In general, the period of normalization of stools in Group 1 (Normobact L) was significantly less than in Group 2 (Bifidumbacterin): 3.24 ± 0.4 days and 4.43 ± 0.2 days, respectively. It was also found that the period of normalization of temperature in Group 1 (Normobact L) was significantly less than in Group 2 (Bifidumbacterin): 53.00 ± 1.98 and 78.3 ± 2.44 h respectively. The body temperature in 100% of patients in the group of children receiving Normobact L became normal on Day 5, in the group of children receiving Bifidumbacterin on Day 7.
About the Authors
I. A. StekolshchikovaRussian Federation
Yu. O. Voronova
Russian Federation
M. G. Borovkova
Russian Federation
L. V. Andreeva
Russian Federation
Yu. V. Danilova
Russian Federation
References
1. Krasnov MV, Akimova VP, Stekolshchi kova IA, Andreeva LV. Clinical and epidemiological features of rotavirus infection in children. Meditsinskiy Almanakh, 2016, 5 (45): 229-231.
2. Bakradze MD, Tatochenko VK, Starovoitova EV. Diagnostic and therapeutic approaches to acute gastroenteritis in children. Voprosy Sovremennoj Pediatrii, 2007, 6 (3): 18-23.
3. Lobzin YuV, Anokhin VA, Khali ullina SV. Acute intestinal infections in children. A fresh look at an old problem. Rossiyskiy Mediko-biologicheskiy Vestnik Imeni Akademika I.P. Pavlova, 2014, 3.
4. Gorelov AV, Milutina LN, Usenko DV. Clinical guidelines for the diagnosis and treatment of acute intestinal infections in children. A guide for practitioners. M., 2006. 91 p.
5. Uchaykin VF, Novokshonov AA, Mazankova LN, Sokolova NV. Acute intestinal infections in children (diagnosis, classification, treatment): a guide for practitioners. M., 2003, 34 p.
6. Bakradze MD. Rotavirus gastroenteritis in children. Detskiy Vrach, 2007, 3: 6-8
7. WHO Library Cataloging-in-Publication Data 2009. Diarrhoea: Why children are still dying and what can be done. The United Nations Children’s Fund (UNICEF)/World Health Organization (WHO), 2009.
8. Szajewska H, Guarino A, Hojsak I, Indrio F, Kolacek S, Shamir R, Vandenplas Y, Weizman Z. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr, 2014, Apr, 58(4): 531–539.
9. Acute diarrhea in adults and children: a global perspective / World Gastroenterology Organisation Global Guidelines [Электронный ресурс]. 2012. URL: http://www.worldgastroenterology.org/assets/export/userfiles/AcuteDiarrhea_long_FINAL_120604.pdf.
10. Guarino A et al. European Society for Pediatric Gastroenterology, Hepatology аnd Nutrition / European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr, 2008, 46(2): 81-122.
11. Szajewska H. Advances and limitations of evidence-based medicine – impact for probiotics. Ann Nutr Metab, 2010, 57(Suppl.): 6-9.
12. Guarino A, Albano F, Ashkenazi S, Gendrel D, Hoek stra JH, Shamir R, Szajewska H. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition / European Society for Paediatric Infectious Diseases Evidence-based Guidelines for the Mana gement of Acute Gastroenteritis in Children in Europe. J Pediat Gastroenterol Nutr, 2008, 46(2): 81-122.
Review
For citations:
Stekolshchikova IA, Voronova YO, Borovkova MG, Andreeva LV, Danilova YV. Experience in clinical using normobact l sinbiotic in combination therapy of acute intestinal infections of virus etiology in children. Meditsinskiy sovet = Medical Council. 2018;(11):154-157. (In Russ.) https://doi.org/10.21518/2079-701X-2018-11-154-157